Do breast cancer patients stick to their meds? new study aims to find out
NCT ID NCT06650423
First seen Mar 28, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This study will follow 319 women with early-stage, hormone-sensitive, HER2-negative breast cancer to see how well they take their prescribed aromatase inhibitors, with or without the added drug abemaciclib. Researchers will measure adherence using pill counts and questionnaires at 3 and 6 months. They also want to understand how quality of life, thinking skills, and attitudes toward medication affect adherence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Oncology Ljubljana
RECRUITINGLjubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aromatase inhibitors (letrozole, anastrozole, exemestane) with or without abemaciclib
What this could lead to
If successful, this study could reveal why some patients stop taking their breast cancer pills and help doctors improve long-term treatment adherence.
What could go wrong
This is an observational study, not a treatment trial. It will not test whether the drugs work better or worse, only how consistently patients take them.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.